138 related articles for article (PubMed ID: 14613028)
1. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.
Allen LF; Eiseman IA; Fry DW; Lenehan PF
Semin Oncol; 2003 Oct; 30(5 Suppl 16):65-78. PubMed ID: 14613028
[TBL] [Abstract][Full Text] [Related]
2. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.
Allen LF; Lenehan PF; Eiseman IA; Elliott WL; Fry DW
Semin Oncol; 2002 Jun; 29(3 Suppl 11):11-21. PubMed ID: 12138393
[TBL] [Abstract][Full Text] [Related]
3. CI-1033, a pan-erbB tyrosine kinase inhibitor.
Slichenmyer WJ; Elliott WL; Fry DW
Semin Oncol; 2001 Oct; 28(5 Suppl 16):80-5. PubMed ID: 11706399
[TBL] [Abstract][Full Text] [Related]
4. Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?
Dewji MR
J Chemother; 2004 Nov; 16 Suppl 4():44-8. PubMed ID: 15688609
[TBL] [Abstract][Full Text] [Related]
5. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
6. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance.
Sonne-Hansen K; Norrie IC; Emdal KB; Benjaminsen RV; Frogne T; Christiansen IJ; Kirkegaard T; Lykkesfeldt AE
Breast Cancer Res Treat; 2010 Jun; 121(3):601-13. PubMed ID: 19697122
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo.
Nyati MK; Maheshwari D; Hanasoge S; Sreekumar A; Rynkiewicz SD; Chinnaiyan AM; Leopold WR; Ethier SP; Lawrence TS
Clin Cancer Res; 2004 Jan; 10(2):691-700. PubMed ID: 14760092
[TBL] [Abstract][Full Text] [Related]
9. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor.
Gonzales AJ; Hook KE; Althaus IW; Ellis PA; Trachet E; Delaney AM; Harvey PJ; Ellis TA; Amato DM; Nelson JM; Fry DW; Zhu T; Loi CM; Fakhoury SA; Schlosser KM; Sexton KE; Winters RT; Reed JE; Bridges AJ; Lettiere DJ; Baker DA; Yang J; Lee HT; Tecle H; Vincent PW
Mol Cancer Ther; 2008 Jul; 7(7):1880-9. PubMed ID: 18606718
[TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
12. Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Mayordomo C; García-Recio S; Ametller E; Fernández-Nogueira P; Pastor-Arroyo EM; Vinyals L; Casas I; Gascón P; Almendro V
J Cell Physiol; 2012 Apr; 227(4):1358-66. PubMed ID: 21604273
[TBL] [Abstract][Full Text] [Related]
13. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
16. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors.
Lin NU; Winer EP
Breast Cancer Res; 2004; 6(5):204-10. PubMed ID: 15318926
[TBL] [Abstract][Full Text] [Related]
17. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.
Fuller SJ; Sivarajah K; Sugden PH
J Mol Cell Cardiol; 2008 May; 44(5):831-54. PubMed ID: 18430438
[TBL] [Abstract][Full Text] [Related]
18. Canertinib induces ototoxicity in three preclinical models.
Tang J; Qian Y; Li H; Kopecky BJ; Ding D; Ou HC; DeCook R; Chen X; Sun Z; Kobel M; Bao J
Hear Res; 2015 Oct; 328():59-66. PubMed ID: 26163095
[TBL] [Abstract][Full Text] [Related]
19. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
20. Impact of ErbB Receptors and Anticancer Drugs against Breast Cancer: A Review.
Sahu A; Verma S; Varma M; Yadav MK
Curr Pharm Biotechnol; 2022; 23(6):787-802. PubMed ID: 34825638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]